HeartSciences Inc.
HSCS Nasdaq· Finance Services
Last close · Oct 26, 2026
$3.18
KIRA · Stoqly’s AI analyst, in plain words
- HeartSciences Inc. had $0.0M of revenue in fiscal 2026, down 2.3% on the year before.
- Its operating margin was −195,648.8%, down 5,817.0 pts: of every 100 in sales, about −195,649 is left after running the business.
- HeartSciences Inc. lost $9.1M in fiscal 2026.
- Free cash flow was −$7.4M in fiscal 2026, −172,797.7% of revenue.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$9.1M
Free cash flow
−$7.4M
Operating margin
−195,648.8%
HeartSciences Inc. in 30 seconds · fiscal 2026
Are sales growing?
−2.3%
No. Sales fell 2.3% last year.
Does it make a profit?
−212,602.3%
No. It lost money last year.
Does profit turn into cash?
−172,797.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
What HeartSciences Inc. does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 23, 2026
- Legal name
- HeartSciences Inc.
- CIK
- 0001468492
HeartSciences Inc. · HSCS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Revenue growth | — | −63.9% | 257.7% | −76.3% | −2.3% |
| Gross margin | 45.1% | 46.2% | 67.2% | 56.8% | 60.5% |
| Operating margin | −32,704.2% | −117,557.7% | −33,902.2% | −189,831.8% | −195,648.8% |
| Net income | −$4.8M | −$6.4M | −$6.6M | −$8.8M | −$9.1M |
| Net margin | −33,529.9% | −122,198.1% | −35,511.8% | −199,209.1% | −212,602.3% |
| Diluted EPS | −$1.45 | −$80.00 | −$18.74 | −$9.34 | — |
| Cash | |||||
| Cash from operations | −$3.6M | −$5.8M | −$6.1M | −$7.4M | −$7.4M |
| Capital expenditure | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$3.6M | −$5.8M | −$6.1M | −$7.4M | −$7.4M |
| FCF margin | −25,319.4% | −111,382.7% | −32,982.3% | −168,550.0% | −172,797.7% |
| Share count change | — | −97.6% | 343.4% | 166.2% | — |
| Debt and strength | |||||
| Cash and short-term investments | $0.9M | $1.7M | $5.8M | $1.1M | $1.7M |
| Shareholders' equity | −$6.1M | $0.2M | $7.3M | $0.2M | $0.2M |
| Current ratio | 0.6x | 1.5x | 4.2x | 0.6x | 0.5x |
| Interest coverage | −12.7x | −25.1x | −17.8x | −16.7x | −11.2x |
| Returns and quality | |||||
| Return on equity | — | — | −175.0% | −233.0% | −4,239.2% |
| Return on tangible equity | — | −2,755.6% | −115.3% | — | — |
| Piotroski F-score | — | 5 | 5 | 1 | 3 |
| Altman Z'' | −105.6 | −70.9 | −20.2 | −74.4 | −66.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
HeartSciences Inc. · HSCS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.18 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001468492). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.